X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (40) 40
index medicus (30) 30
melanoma (27) 27
female (20) 20
male (19) 19
oncology (19) 19
adult (17) 17
middle aged (17) 17
cancer (15) 15
aged (13) 13
metastatic melanoma (13) 13
research (12) 12
survival (12) 12
ipilimumab (11) 11
immunotherapy (9) 9
melanoma - drug therapy (9) 9
melanoma - pathology (9) 9
metastasis (9) 9
patients (9) 9
skin neoplasms - pathology (9) 9
immunology (8) 8
prognosis (8) 8
studies (8) 8
drug therapy (7) 7
hematology (7) 7
animals (6) 6
cell biology (6) 6
overall survival (6) 6
skin neoplasms - drug therapy (6) 6
therapy (6) 6
tumor cells, cultured (6) 6
analysis (5) 5
antibodies, monoclonal - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
apoptosis (5) 5
article (5) 5
biochemistry & molecular biology (5) 5
biology (5) 5
clinical trials (5) 5
expression (5) 5
genetic aspects (5) 5
genetics & heredity (5) 5
genome-wide association study (5) 5
medical and health sciences (5) 5
medical research (5) 5
medicin och hälsovetenskap (5) 5
medicine & public health (5) 5
metastases (5) 5
neoplasm staging (5) 5
polymorphism, single nucleotide (5) 5
treatment outcome (5) 5
best overall response (4) 4
binding (4) 4
body mass index (4) 4
cholecalciferol - pharmacology (4) 4
clinical medicine (4) 4
ctla-4 protein (4) 4
ctla-4 variants (4) 4
differentiation (4) 4
disease-free survival (4) 4
experience (4) 4
health aspects (4) 4
medical prognosis (4) 4
melanoma - immunology (4) 4
melanoma - secondary (4) 4
mice (4) 4
mutation (4) 4
neoplasm proteins - genetics (4) 4
obesity - genetics (4) 4
phenotype (4) 4
predictive/prognostic factor (4) 4
risk factors (4) 4
survival analysis (4) 4
transcription factors - genetics (4) 4
transforming growth factor beta - pharmacology (4) 4
tretinoin - pharmacology (4) 4
tumors (4) 4
variants (4) 4
3t3 cells (3) 3
age factors (3) 3
aged, 80 and over (3) 3
antibodies (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
architecture (3) 3
biological sciences (3) 3
cancer research (3) 3
cancer vaccines - therapeutic use (3) 3
care and treatment (3) 3
cell differentiation - drug effects (3) 3
cell-line (3) 3
chemotherapy (3) 3
cytoplasm - metabolism (3) 3
dermatology (3) 3
development and progression (3) 3
disease (3) 3
diseases (3) 3
gene (3) 3
genomes (3) 3
heat-shock proteins - therapeutic use (3) 3
hsp (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Research, ISSN 0008-5472, 10/2014, Volume 74, Issue 19 Supplement, pp. 2550 - 2550
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. e20060 - e20060
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. e20037 - e20037
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1480 - 1492
Journal Article
Cancer Research, ISSN 0008-5472, 04/2012, Volume 72, Issue 8 Supplement, pp. 5556 - 5556
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 879 - 886
Journal Article
Cytokine & growth factor reviews, 08/2017, Volume 36, p. 1
The explosion in the immuno-oncology field, exemplified by the clinical implementation of immune checkpoint inhibitor blockade and other immunotherapeutic... 
Information Services - trends | Neoplasms - therapy | Biological Therapy - trends | Neoplasms - immunology | Humans | Immunotherapy | Italy | Goals | Information Services - organization & administration
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2019, Volume 111, Issue 8, pp. 772 - 781
We previously showed that therapy with anti-CTLA-4 or anti-PD-1 agents was more effective for men as compared with women. However, since the sex-dimorphism of... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2017, Volume 35, Issue 34, pp. 3815 - 3822
Purpose The addition of nivolumab (anti-programmed death-1 antibody) to ipilimumab (anti-cytotoxic T-cell lymphocyte-associated 4 antibody) in patients with... 
ANTIBODIES | SURVIVAL | METASTATIC MELANOMA | MONOTHERAPY | ANTI-CTLA-4 | ONCOLOGY | CANCER | ADVERSE EVENTS | Index Medicus
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.